Scribe Therapeutics, Inc.

Overview

Compare with another stock.

• TickerSCTX on Nasdaq¹
• IndustryBiological Products, (No Diagnostic Substances)¹
• HeadquartersAlameda, California¹
• Incorporated inDE²
• Business address1150 Marina Village Pkwy, Alameda, Ca 94501²
• Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²

See how the biggest companies compare on our leaderboards

Corporate structure

Scribe Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Scribe Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerBenjamin L. Oakes Jul 23, 2026 to now³
• PresidentBenjamin L. Oakes Jul 23, 2026 to now³
• Chief financial officerDavid Parrot Jul 23, 2026 to now⁴

Timeline

1. Sep 2, 20268-K Results of operations⁹
2. Jul 27, 20268-K Bylaws or fiscal year changed¹⁰
3. Jul 23, 2026New chief executive Benjamin L. Oakes becomes CEO³

Calendar

Coming up

1. Dec 2, 2026Reports results for the quarter ending Sep/2026¹¹

When it reported results

1. Sep 2, 2026Reported quarterly or annual results⁹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

45 filings to the SEC since October 2021: 1 quarterly reports, 2 major events, 25 insider forms, 4 large holders, 13 other. The latest 20:

1. Sep 2, 202610-Q EDGAR
2. Sep 2, 20268-K EDGAR
3. Aug 3, 2026SCHEDULE 13G EDGAR
4. Jul 30, 2026SCHEDULE 13D EDGAR
5. Jul 30, 2026SCHEDULE 13D EDGAR
6. Jul 29, 20264 EDGAR
7. Jul 29, 20264 EDGAR
8. Jul 29, 20264 EDGAR
9. Jul 29, 20264 EDGAR
10. Jul 29, 2026SCHEDULE 13D EDGAR
11. Jul 28, 20264 EDGAR
12. Jul 28, 20264 EDGAR
13. Jul 27, 20264 EDGAR
14. Jul 27, 20264 EDGAR
15. Jul 27, 20264 EDGAR
16. Jul 27, 20264 EDGAR
17. Jul 27, 20264 EDGAR
18. Jul 27, 20264 EDGAR
19. Jul 27, 20268-K EDGAR
20. Jul 27, 2026S-8 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 7 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G, 1 filing Aug 3, 2026¹²
• Avoro Capital Advisors LLCSCHEDULE 13D, 1 filing Jul 30, 2026¹³
• Eli Lilly and CompanySCHEDULE 13D, 1 filing Jul 30, 2026¹⁴
• ORBIMED ADVISORS LLCSCHEDULE 13D, 1 filing Jul 29, 2026¹⁵

SEC filer profile

How Scribe Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARScribe Therapeutics, Inc.¹
• CIK0001853921
• Employer ID (EIN)82-2157847¹
• Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address1150 Marina Village Pkwy, Alameda, CA 94501¹
• Phone510-454-0213¹
• Shares outstanding18,931,680 as of Aug 31, 2026¹⁶
• On EDGAR sinceApr 2, 2021¹
• Filings46 in all: 4 (13), 3 (12), SCHEDULE 13D (3), 8-K (2), DRS/A (2), S-1/A (2), 10-Q (1), 424B4 (1)¹
  All 18 form types

  8-A12B (1), CERT (1), D (1), DRS (1), EFFECT (1), FWP (1), S-1 (1), S-1MEF (1), S-8 (1), SCHEDULE 13G (1)

• Latest filingsQuarterly report (10-Q) Sep 2, 2026
  Latest 8-K (8-K) Sep 2, 2026